Novo Nordisk said it expects its 2026 sales to remain flat despite a shift in the competitive obesity landscape, citing performance from Wegovy’s pill. The company also indicated that CagriSema will not launch in Europe for “a couple of years,” pointing to the need for new European trials. In parallel, reporting around Novo’s guidance and CFO commentary suggests investors are increasingly focused on near-term volume execution and on whether oral incretin combinations can close the gap with injectable incumbents. Novo’s updates come as Eli Lilly continues to scale its tirzepatide franchise and as the weight-loss market accelerates toward oral formulations. While the articles do not provide detailed trial metrics here, they reinforce that development execution and launch sequencing remain core determinants of competitive dynamics in obesity therapeutics. For the sector, these communication moves signal Novo’s intent to defend its injectable lead while preparing for the next platform shift toward oral therapies across geographies.